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"Intellectual Property at the Public-Private
Divide:" A Response
ABBEY S. MEYERSt
Rebecca S. Eisenberg's scholarly article examines United States patent law's
application t6 complementary DNA ("cDNA") sequencing,' a unique new area
of scientific technology that was certainly never envisioned by the authors of
patent legislation. However, arguing in favor of DNA patenting seems some-
what akin to arguing from the constitutional right to bear arms to the right of
homeowners to own cannons. Some would argue that the right to bear arms
means that every red-blooded American has the right to protect his or her
property through any means possible and the Constitution does not differenti-
ate between rifles and cannons. Similarly, the Constitution is mute on the topic
of DNA. As a result, some would argue that the same patent laws that were
created to protect designers of plows and tonics can be easily applied to this
new area of science.
As a "consumer" who is also a mother, a grandmother, a leader of a
national voluntary health agency that is very involved with genetic diseases,
and a member of the human race, I must express my concern about what I
consider a moral and ethical outrage. No matter what a court of law would
decide about the patentability of DNA, in my mind, there is a difference
between a "discovery" and an "invention." Human beings did not invent
DNA; therefore, there is no way any civilized society should allow human
beings to patent it, especially before all of its uses are known. The law's
unwillingness to address the unique concerns raised by genetic discoveries has
brought humanity to a precipice of risk with unimaginable consequences only
a step away. The cells of our progeny are being sold before they are even
conceived.
The main patent controversy Eisenberg addresses involves cDNA sequenc-
ing. Companies and researchers are applying for patents on DNA sequences
before all of their uses are known and certainly before any diagnostic or
therapeutic application has been identified. Moreover, American taxpayers have
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1. See Rebecca S. Eisenberg, Intellectual Property at the Public-Private Divide: The
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paid a very large part of the bill for the development of sequencing technolo-
gy, but still have no hope of recovering their investment. Indeed, we will pay
for it twice. We have paid once for the research and development of sequenc-
ing itself and will be forced to pay again if we wish to use any diagnostic or
therapeutic products that are developed from DNA sequences.
Perhaps we taxpayers should demand royalties from the companies who
use publicly-supported research to develop lucrative products. At the very least,
we might elicit a pledge from these companies to charge reasonable prices
when their products reach the commercial market. Unfortunately, the pharma-
ceutical industry has lobbied intensely against such ideas and has even con-
vinced the government to repeal "reasonable pricing" language from Coopera-
tive Research and Development Agreements ("CRADAs"), which give commer-
cial sponsors the rights to produce, market, and profit from government
inventions.2
Let me make it very clear that the patient community, through voluntary
health agencies such as the National Organization for Rare Disorders
("NORD"), absolutely supports the right of inventors to seek and obtain
patents. Indeed, my personal involvement in this field began years ago when
one of my children was taking an experimental drug that was discontinued
because the manufacturer believed the drug would be unprofitable since so few
children had the disease. Subsequently, I put together a coalition of national
voluntary health agencies devoted to rare disorders in order to advocate the
federal legislation that is now known as the Orphan Drug Act.' This law
contains a group of financial incentives that are designed to entice pharma-
ceutical companies to develop drugs that, without such incentives, would have
little commercial value.
The main incentive provided by the Orphan Drug Act is a seven-year
period of exclusive marketing rights4 during which no other company is
permitted to market the same drug for the same disease. Clearly, this period
of exclusivity was designed to function as a surrogate patent. Initially, we
thought that only those companies developing unpatentable drugs or old drugs
whose patents had expired would be interested in this incentive. However,
biotechnology companies soon began using orphan drug exclusivity to prevent
competition because they did not believe that U.S. patent law was secure
enough to guarantee a monopoly on any biologic. The patent application
process often took years before a patent was issued, and then some patents
2. David S. Hilzenrath, NIH Drops Its Policy on Drug Prices, Wash Post F1 (Apr
12, 1995); National Institutes of Health, NIH News (Apr 11, 1995) (press release an-
nouncing removal of the "reasonable pricing" clause from the Public Health Service model
CRADA and the PHS Exclusive License Agreement). See also United States Senate, Special
Committee on Aging, Pryor Releases OIG Study on Integrity of NIH CRADA Process,
Aging News (Nov 23, 1993).
3. Orphan Drug Act, Pub L No 97-414, 96 Stat 2049 (1983), codified at 21 USC
S 301, S 360 et seq (1994).
4. 21 USC S 360cc (1994).
[3:581
Intellectual Property: A Response 583
only covered the manufacturing methodology or the "use" of the drug rather
than the product itself.
Recognition of the Orphan Drug Act's success, largely a result of its
exclusivity provisions, absolutely confirms that patents, which reward inventors
by conferring monopoly rights, are powerful incentives. However, patents on
DNA are strikingly different from drug patents. A monopoly on a gene or
gene sequence is likely to inhibit the development of other products related to
that gene and, thereby, prevent humanity from accessing important medical
benefits. As a consequence, I believe that patents on DNA as it exists in nature
should be prohibited, although patents on products that are made with DNA
discoveries should be encouraged. The decisive factor in granting patents
should be whether human creativity was required to manipulate what nature
has given us in order to design a useful product. For example, unaltered DNA
is not a useful product, but the proteins made by DNA may be useful if one
can figure out how to manufacture large quantities of them.
Under current law, a person or institution who owns a gene or gene
sequence can potentially hold the human race hostage. The scientist who
"owns" a gene has the frightening ability to demand any price from another
scientist who wishes to study it, as well as the ability to demand future reward
for any discoveries yet to be made by other researchers. More than simply
denying other scientists financial benefits, the ability to set conditions for
access to a gene is earth-shattering to families with genetic diseases. Keeping
knowledge about any segment of the human genome from the public domain
is immoral. If you understand your own personal lifetime risk for common
genetic diseases such as cancer, hypertension, and heart disease, you under-
stand that all of us will be affected by this very serious debate whether it is
settled in our courts, our churches, or our own living rooms.
One of the most important lessons we have learned from the success of
the Orphan Drug Act is that the pharmaceutical/biotechnology industry is
extremely adept at developing "me-too" drugs that vary insignificantly from
pioneer drugs. In fact, "me-too" drugs vary only as much as is absolutely
necessary to get on the market without infringing the pioneer drug's patent.
On the contrary, if a gene or gene sequence is patented by the pioneer
company, there will be no free access to the building blocks of the "me-too"
drugs. Therefore, since large pharmaceutical companies are buying sequencing
companies, they may own the mortgage on our future. Companies with patents
on important genes or gene sequences will be able to prevent access to these
genes by any potential competitor for twenty years.
To keep the issue in focus, we must understand that there is a difference
between a patent on a widget and a patent on a gene sequence. Perhaps the
widget is needed to advance a technology, improve a manufacturing process,
enhance communications, or make something more efficient or attractive. By
comparison, genes are needed for much more critical reasons. Often a gene
and/or knowledge about its function can mean the difference between life and
death to multitudes of patients. It is immoral to keep this knowledge secret
simply to garner an advantage over possible competitors. It is unethical to
1996]
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charge a ransom for access to such potentially life-saving knowledge. Our
concerns are even greater if the sequence is owned by a company without
expertise in these types of diseases or if a corporate patent owner decides that
the disease is too rare to make the kinds of profits its shareholders expect.
Genes and their therapeutic or diagnostic products could languish in a labo-
ratory while children are dying.
When the National Institutes of Health ("NIH") filed patent applications
a few years ago for sequences that the government had discovered, I was
personally delighted. This meant that the American government would own
these sequences and would likely put them in the public domain. However,
when the pharmaceutical/biotechnology industry objected vehemently, the
patent office denied the patents to the NIH. Why then is private industry
continuing to file patents on gene sequences? If it was not good for the goose,
why is it good for the gander? The industry's motivation seems transparent.
The companies want to make big money out of every gene that they can keep
away from the taxpayer. Sometimes it seems that everyone is making a buck
off of the genome enterprise at the expense of the patients.
Who should be the beneficiaries of all of these sequence databases?
Intellectual property strategies that benefit some players will harm others. Cer-
tainly a large proportion of those "others" are the patients. One must wonder
whether Wall Street's myopic focus on short-term gain should be allowed to
eclipse the long-term medical payoff for which society is waiting. With all of
the concern about profits and stock prices, we may be delaying the medical
progress that might be possible if more people from different institutions were
able to make queries on the various gene databases.' As a consumer, I do not
really care what Merck & Co.'s motivation is in placing its database in the
public domain. The important fact is that the company did so. It was the right
thing to do for society, and people with genetic diseases are sincerely grateful.
Where are the boundaries between private interests and public need?
Europe, for example, seems to be more sensitive to social engineering ques-
tions, probably because of World War II and the Holocaust. In general,
Europe has very weak patent laws governing biotechnology drugs. Any time
the European Parliament considers strengthening those patent laws, the effort
fails. Whether or not they try again, as they likely will, no biotechnology
company has refused to market its products in Europe. For example, there are
more than five different brands of recombinant human growth hormone (r-
hGH) on the market in Europe. While this drug sells for more than $30,000
per year of treatment in the United States, the only effect of the competition
in Europe has been to reduce the price by at least 15 percent. This shows that
the standard pharmaceutical industry defense, that they will not continue their
genetic research without patents, is simply fictitious.6 The absence of patents
would certainly make drug manufacturing more competitive and less lucrative,
5. See Eisenberg, 3 U Chi L Sch Roundtable at 567 (cited in note 1).
6. George Poste, The case for genomic patenting, 378 Nature 534, 535 (1995).
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but these companies are not about to close up shop and go into the shoe
business.
Nothing illustrates the socioeconomic genomic dilemma better than the
controversy surrounding human gene therapy. Let me preface these remarks by
saying that I am a member of the NIH Recombinant DNA Advisory Commit-
tee ("RAC"), which oversees gene therapy experiments in the United States.
The Committee was created in the 1970s because of public concern that
genetic experimentation might cause a biological catastrophe and/or change the
human race. Therefore, the committee has always met publicly and has al-
lowed public input into its discussions and any of its decisions regarding DNA
research.
The first human gene therapy protocols commenced in 1990. Besides
approving or disapproving new protocols, the RAC also periodically reviews
data management reports from ongoing investigations to determine whether: (a)
the gene has been successfully transferred into cells; (b) adverse events have
occurred; and (c) there is evidence of a therapeutic effect. Unfortunately, the
only conclusion that we have been able to draw in the past five years is that
gene therapy does not work.7
Meanwhile, biotechnology companies who sponsor these clinical human
gene therapy trials are issuing very positive press releases aimed primarily at
Wall Street. Reports of miraculous experiments seep into the popular press and
the public becomes overwhelmed with the good news. Seriously ill people with
hopeless diseases demand immediate access to gene therapy trials through their
Congressmen and Senators. Yet, every three months, when the RAC holds
public meetings, it is inevitably revealed that most of the new protocols simply
replicate other previously approved trials that have already demonstrated that
gene therapy does not work. While gene therapy will undoubtedly work
someday, much more basic research is needed before this technology can be
translated into therapeutic advancements.
The truth seems too painful for the industry to bear, probably because it
must meet Wall Street's short-term goals. Instead of redoubling its efforts
through increased basic research or designing new and improved vectors, the
industry has launched a major lobbying campaign to dissolve the Recombinant
DNA Advisory Committee.! If there are no public meetings, the press will not
have access to the truth. As a result, investors will continue to believe that
there will be a short-term payoff because they will continue to believe incor-
rectly that gene therapy will ioon be commercialized. Moreover, if these com-
panies continue to report that they are working on prevalent and lucrative dis-
eases, such as cancer, more investors will be attracted to these cash-starved
companies.' In general, LiffS creates financial itcentives for the industry to
7. Eliot Marshall, Less Hype, More Biology Needed for Gene Therapy, 270 Sci 1751
(19S*-) (citing National Institutes of Health, Report and Recommendations of the Panel to
Assess the NIH Investment in Research on Gene Therapy (Dec 7, 1995)).
8. Jocelyn Kaiser, Science Scope: RAC Faces Uncertain Future, 269 Sci 1659 (1995).
9. Abbey S. Meyers, Editorial: Gene Therapy and Genetic Diseases: Revisiting the
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continue to pursue unsuccessful protocols in lieu of protocols on rare genetic
diseases that might be more easily cured, but are not as potentially lucra-
tive."
In 1995, NIH Director Harold Varmus appointed a special committee to
study the NIH's role in gene therapy research. On December 7, 1995, the
committee, chaired by Dr. Stuart Orkin and Dr. Arno Motulsky, issued its
report stating that gene therapy does not work. They concluded that much
more basic research is needed before gene therapy technology can be successful
and found that scientists, institutions, and drug companies have misrepresented
the truth in their communications with the public because they are overly
concerned with attracting public acclaim and venture capital." The committee
advised the scientific community to go back to the drawing board, seeking to
improve the technology without the hype that has delayed advancements and
fooled the public.'
To patient advocates such as me, the most disturbing aspect of all these
genome-related controversies is the fact that the truth is being subverted solely
for profit and at the cost of human suffering. Unfortunately, our society seems
unwilling to recognize the consequences of this sequence patenting controversy
until it is too late.
Rather, we must open our eyes to the fact that we are not dealing with oil
wells or widgets. Quite simply, we are dealing with the human race as we
know it. For example, while Henry Ford clearly deserved to get a patent on
the Model T, imagine what would have happened if he had received a patent
on the automobile. Would he have prevented General Motors and Chrysler
from making "me-too" cars? You bet he would have. Yet, if Ford held a
monopoly on automobiles for twenty years, people would not have died from
the absence of Chevrolets. Today, however, if a drug company or scientist
receives a monopoly on a gene sequence for twenty years, people may die from
the absence of drugs or therapies that other drug companies or scientists could
have developed with the knowledge of that patented gene sequence. An
academic scientist should not have to hire a lawyer to determine whether or
not he or she can pursue a promising line of genetic research because someone
else may have a patent on a relevant chromosome or gene. If all sequences
were in the public domain, both academic and commercial scientists' inventions
would be encouraged and facilitated. After all, this is the purpose of patent
law-the benefit of society.
As Professor Eisenberg so aptly notes, "we may need to reconsider the
limits of private appropriation of new information as a means of promoting
Promise, 5 Human Gene Therapy 1201, 1201-02 (1994).
10. W. French Anderson, Editorial: Yes, Abbey, You Are Right, 5 Human Gene Thera-
py 1199, 1199-1200 (1994).
11. See generally National Institutes of Health, Report and Recommendations of the
Panel to Assess the NIH Investment in Research on Gene Therapy (Dec 7, 1995).
12. Id.
[3:581
Intellectual Property: A Response 587
commercial development." 3 In my mind, the only question is why society has
so little sense of urgency to do what must inevitably be done.
13. Eisenberg, 3 U Chi L Sch Roundtable at 573 (cited in note 1).
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